Clopidogrel of loading dosage to treat acute ischaemic stroke in China (CLASS-CHINA)
| ISRCTN | ISRCTN07057952 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN07057952 |
| Secondary identifying numbers | CLASS-CHINA-2007-10-08 |
- Submission date
- 05/03/2008
- Registration date
- 14/03/2008
- Last edited
- 08/02/2010
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English Summary
Not provided at time of registration
Contact information
Prof Anding Xu
Scientific
Scientific
Huangpu Avenue West 601
Department of Neurolgy
The First Affiliated Hospital
Jinan University Guangzhou
Guangzhou
510630
China
| Phone | +86 20 38688305 |
|---|---|
| adx63@sohu.com |
Study information
| Study design | Multicenter, randomized, double-blind placebo controlled, parallel group study. |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Not specified |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | Clopidogrel of loading dosage to treat acute ischaemic stroke in China (CLASS-CHINA): A randomized double-blind parallel controlled clinical trial |
| Study acronym | CLASS-CHINA |
| Study hypothesis | Early recurrence of ischemic stroke/transient ischaemic attack (TIA) within 7 days occurs at a rate of about 2-8%, and deterioration (Stroke in Progression, SIP) is known to occur at about 30% or an even higher rate. In addition to thrombolysis, aspirin is the only proved effective agent for patients with acute ischemic stroke. However, the net benefit of aspirin is small. There is therefore a medical need to ensure a better protection against the early recurrence or deterioration of ischemic stroke. Clopidogrel is superior to aspirin for second prevention for ischemic stroke, and pharmacokinetic data showed that conventional regimen of clopidogrel administration (75 mg/d) need 7 days to reach the optimal platelet inhibition effect, while 300 mg loading dose regimen, i.e. 300 mg initiation followed by 75 mg/d can reach the maximum platelet inhibition effect within 3 hours. Our pilot trial demonstrated a clear benefit trend of loading dose clopidogrel (300 mg) better than daily 75 mg of clopidogrel in patients with acute cerebral infarction/TIA. Therefore, we hypothesized that loading dose clopidogrel is effective and safe for patients with acute cerebral infarction caused by atherothrombosis. |
| Ethics approval(s) | Ethics Committee of the First Affiliated Hospital, Sun Yat-Sen University Guangzhou. Date of approval: 07/01/2008. |
| Condition | Acute ischaemic stroke |
| Intervention | Two arms: 1 Loading dose (LD) group: patients will receive a 300 mg loading dose of clopidogrel right after randomization, followed by daily 75 mg clopidogrel for the next 27 days (total 28 days) 2 Routine dose group: patients will receive 75 mg clopidogrel and 3 tablets of placebo right after randomization, followed by daily 75 mg clopidogrel for the next 27 days (total 28 days) Both arms will be given basic treatments at the discretion of the responsible doctor, including anti-hypertension drugs, statins, neuroprotetives, etc, except for aspirin or any other antiplatelet drugs. Chinese herbal products affecting platelet functions cannot not be prescribed. During the observation period, if patients experience SIP or recurrence of ischemic stroke, clopidogrel may be stopped, and other antithrombotic therapy, i.e. anticoagulants, or others may be used at the discretion of the responsible doctor. Please note that as of 08/02/10 the anticipated end date of this trial has been updated from 31/08/09 to 31/05/10. Due to issues with patient recruitment, enrollment in this trial has been suspended. An intermediate analysis will be carried out in May 2010, once the follow up period for all patients is competed. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Clopidogrel |
| Primary outcome measure | Stroke recurrence or SIP (evaluated by the National Institutes of Health Stroke Scale [NIHSS]) within 7days. |
| Secondary outcome measures | 1. Death or dependence (modified Rankin Scale [mRS] >=3) at 28 and 90 days 2. Death or stroke recurrence within 28 days 3. Stroke recurrence, acute myocardial infarction or vascular death with 28 days 4. Bleeding: Life-threatening bleeding, major bleeding and minor bleeding |
| Overall study start date | 28/02/2008 |
| Overall study end date | 31/05/2010 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Upper age limit | 80 Years |
| Sex | Both |
| Target number of participants | 600 |
| Participant inclusion criteria | 1. Aged 18-80 years 2. Ischemic stroke (IS) within 48 hrs with evidence of computerised tomography (CT) or magnetic resonance imaging (MRI) 3. Satisfying the criteria of partial anterior circulation infarction (PACI) of Oxfordshire Community Stroke Project (OCSP) classification, and large artery atherothrombosis (LAA) of TOAST (the Trial of Org 10172 in Acute Stroke Treatment) classification 4. Informed consent of patient |
| Participant exclusion criteria | 1. Patients planned for thrombolysis 2. Any of the following: 2.1. Cardiogenic cerebral embolism 2.2. Lacuna cerebral infarction 2.3. Total anterior circulation cerebral infarction 2.4. Posterior circulation cerebral infarction 2.5. Cerebral infarction of the etiology rather than atherothrombosis and unidentified etiology 3. History of allergic reaction to clopidogrel 4. Patients regularly took oral anticoagulants (OAC), heparin or molecular weight heparin (LMWH), thienopyridine (clopidogrel or ticlopidine), aspirin (acetylsalicylic acid) >50 mg/d, Aggrenox® before the onset; or patients who need long-term use of drugs that affect platelet functions 5. History of bleeding disorders; clinically significant or persistent thrompocytopenia or neutropenia. 6. Women who are pregnant or breast-feeding 7. Patients with planned surgery within the next 1 month; with a recent operation or trauma history. 8. Severe systematic disorders i.e. heart, lung, liver, kidney diseases, or malignant tumor; or severe gastrointestinal disorder affecting the absorption of drug 9. Enrolled in other clinical trials within the past 3 months |
| Recruitment start date | 28/02/2008 |
| Recruitment end date | 31/05/2010 |
Locations
Countries of recruitment
- China
Study participating centre
Huangpu Avenue West 601
Guangzhou
510630
China
510630
China
Sponsor information
Jinan University Guangzhou (China)
University/education
University/education
c/o Prof Anding Xu
Huangpu Avenue West 601
Brain Research Institute
Guangzhou
510630
China
| Phone | +86 20 38688305 |
|---|---|
| adx63@sohu.com | |
| Website | http://english.jnu.edu.cn |
"ROR" |
https://ror.org/02xe5ns62 |
Funders
Funder type
University/education
Jinan University Guangzhou (China)
No information available
The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou (China)
No information available
Sanofi-Aventis (clopidogrel and placebo are offered by Sanofi-Aventis) (France)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
